{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:03:33Z","timestamp":1790363013274,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s11033-022-07586-9","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T17:02:49Z","timestamp":1654102969000},"page":"7687-7695","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Deregulation of purinergic ectoenzyme activity in head and neck cancer promotes immunosuppression"],"prefix":"10.1007","volume":"49","author":[{"given":"Filomena","family":"Marafon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz da Silva Rosa","family":"Bonadiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"de Rocco Donassolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katiuska","family":"Marins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariane Magalh\u00e3es","family":"Zanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greicy Cristine","family":"Kosvosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena Fornari","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Zamoner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9263-4980","authenticated-orcid":false,"given":"Margarete Dulce","family":"Bagatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"7586_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrc.2018.11","volume":"18","author":"CR Leemans","year":"2018","unstructured":"Leemans CR, Snijders PJF, Brakenhoff RH (2018) The molecular landscape of head and neck cancer. Nat Rev Cancer 18:269\u2013282. https:\/\/doi.org\/10.1038\/nrc.2018.11","journal-title":"Nat Rev Cancer"},{"key":"7586_CR2","unstructured":"NIH (2019) Head and Neck Cancer \u2013 Patient Version. https:\/\/www.cancer.gov\/types\/head-and-neck. Accessed May 26, 2021"},{"key":"7586_CR3","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.3892\/ol.2019.10616","volume":"18","author":"F Chen","year":"2019","unstructured":"Chen F, Zheng A, Li F et al (2019) Screening and identification of potential target genes in head and neck cancer using bioinformatics analysis. Oncol Lett 18:2955\u20132966. https:\/\/doi.org\/10.3892\/ol.2019.10616","journal-title":"Oncol Lett"},{"key":"7586_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2020.01020","volume":"10","author":"H Konings","year":"2020","unstructured":"Konings H, Stappers S, Geens M et al (2020) A Literature Review of the Potential Diagnostic Biomarkers of Head and Neck Neoplasms. Front Oncol 10:1\u201318. https:\/\/doi.org\/10.3389\/fonc.2020.01020","journal-title":"Front Oncol"},{"key":"7586_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/njcp.njcp_310_18","volume":"22","author":"AF Alfouzan","year":"2019","unstructured":"Alfouzan AF (2019) Head and neck cancer pathology: Old world versus new world disease. Niger J Clin Pract 22:1\u20138. https:\/\/doi.org\/10.4103\/njcp.njcp_310_18","journal-title":"Niger J Clin Pract"},{"key":"7586_CR6","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41419-019-1769-9","volume":"10","author":"E Alsahafi","year":"2019","unstructured":"Alsahafi E, Begg K, Amelio I et al (2019) Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death Dis 10:540. https:\/\/doi.org\/10.1038\/s41419-019-1769-9","journal-title":"Cell Death Dis"},{"key":"7586_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s11302-013-9396-x","volume":"147","author":"G Burnstock","year":"2006","unstructured":"Burnstock G (2006) Purinergic signalling. J Pharmacol 147:172\u2013181. https:\/\/doi.org\/10.1007\/s11302-013-9396-x","journal-title":"J Pharmacol"},{"key":"7586_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.imlet.2018.11.006","volume":"205","author":"AL Giuliani","year":"2019","unstructured":"Giuliani AL, Sarti AC, Di Virgilio F (2019) Extracellular nucleotides and nucleosides as signalling molecules. Immunol Lett 205:16\u201324. https:\/\/doi.org\/10.1016\/j.imlet.2018.11.006","journal-title":"Immunol Lett"},{"key":"7586_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2398212818817494","volume":"2","author":"G Burnstock","year":"2018","unstructured":"Burnstock G (2018) Purine and purinergic receptors. Brain Neurosci Adv 2:1\u201310. https:\/\/doi.org\/10.1177\/2398212818817494","journal-title":"Brain Neurosci Adv"},{"key":"7586_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/4892473","volume":"1","author":"MD Bagatini","year":"2018","unstructured":"Bagatini MD, Dos Santos AA, Cardoso AM et al (2018) The impact of purinergic system enzymes on noncommunicable, neurological, and degenerative diseases. J Immunol Res 1:1\u201321. https:\/\/doi.org\/10.1155\/2018\/4892473","journal-title":"J Immunol Res"},{"key":"7586_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2017.00661","volume":"8","author":"G Burnstock","year":"2017","unstructured":"Burnstock G (2017) Purinergic signalling: Therapeutic developments. Front Pharmacol 8:1\u201355. https:\/\/doi.org\/10.3389\/fphar.2017.00661","journal-title":"Front Pharmacol"},{"key":"7586_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/nbm.3066.Non-invasive","volume":"16","author":"L Antonioli","year":"2013","unstructured":"Antonioli L, Pacher P, Sylvester Vizi E, Hask\u00f3 G (2013) CD39 and CD73 in immunity and inflammation. Trends Mol Med 16:355\u2013367. https:\/\/doi.org\/10.1002\/nbm.3066.Non-invasive","journal-title":"Trends Mol Med"},{"key":"7586_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00553-z","volume":"6","author":"Z Huang","year":"2021","unstructured":"Huang Z, Xie N, Illes P et al (2021) From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther 6:1\u201324. https:\/\/doi.org\/10.1038\/s41392-021-00553-z","journal-title":"Signal Transduct Target Ther"},{"key":"7586_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4110\/in.2019.19.e23","volume":"19","author":"S Arab","year":"2019","unstructured":"Arab S, Hadjati J (2019) Adenosine blockage in tumor microenvironment and improvement of cancer immunotherapy. Immune Netw 19:1\u201319. https:\/\/doi.org\/10.4110\/in.2019.19.e23","journal-title":"Immune Netw"},{"key":"7586_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11302-013-9372-5","volume":"9","author":"G Burnstock","year":"2013","unstructured":"Burnstock G, Di Virgilio F (2013) Purinergic signalling and cancer. Purinergic Signal 9:491\u2013540. https:\/\/doi.org\/10.1007\/s11302-013-9372-5","journal-title":"Purinergic Signal"},{"key":"7586_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/onc.2016.206","volume":"36","author":"F Di Virgilio","year":"2017","unstructured":"Di Virgilio F, Adinolfi E (2017) Extracellular purines, purinergic receptors and tumor growth. Oncogene 36:293\u2013303. https:\/\/doi.org\/10.1038\/onc.2016.206","journal-title":"Oncogene"},{"key":"7586_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells9071612","volume":"9","author":"ADR Campos-Contreras","year":"2020","unstructured":"Campos-Contreras ADR, D\u00edaz-Mu\u00f1oz M, V\u00e1zquez-Cuevas FG (2020) Purinergic Signaling in the Hallmarks of Cancer. Cells 9:1\u201324. https:\/\/doi.org\/10.3390\/cells9071612","journal-title":"Cells"},{"key":"7586_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-019-1301-1","volume":"36","author":"D Zanini","year":"2019","unstructured":"Zanini D, Manfredi LH, Pelinson LP et al (2019) ADA activity is decreased in lymphocytes from patients with advanced stage of lung cancer. Med Oncol 36:1\u20138. https:\/\/doi.org\/10.1007\/s12032-019-1301-1","journal-title":"Med Oncol"},{"key":"7586_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms222111472","volume":"22","author":"C Dillard","year":"2021","unstructured":"Dillard C, Borde C, Mohammad A et al (2021) Expression pattern of purinergic signaling components in colorectal cancer cells and differential cellular outcomes induced by extracellular atp and adenosine. Int J Mol Sci 22:1\u201323. https:\/\/doi.org\/10.3390\/ijms222111472","journal-title":"Int J Mol Sci"},{"key":"7586_CR20","doi-asserted-by":"publisher","unstructured":"Pfaffenzeller MS, Franciosi MLM, Cardoso AM(2020) Purinergic signaling and tumor microenvironment in cervical Cancer. Purinergic Signal 12\u201314. https:\/\/doi.org\/10.1007\/s11302-020-09693-3","DOI":"10.1007\/s11302-020-09693-3"},{"key":"7586_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.cellsig.2019.03.021","volume":"59","author":"A M\u00e2nica","year":"2019","unstructured":"M\u00e2nica A, da Silva Rosa Bonadiman B, Cardoso AM et al (2019) The signaling effects of ATP on melanoma-like skin cancer. Cell Signal 59:122\u2013130. https:\/\/doi.org\/10.1016\/j.cellsig.2019.03.021","journal-title":"Cell Signal"},{"key":"7586_CR22","first-page":"77","volume":"97","author":"A B\u00f6yum","year":"1968","unstructured":"B\u00f6yum A (1968) Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1\u00a0g. Scand J Clin Lab Invest Suppl 97:77\u201389","journal-title":"Scand J Clin Lab Invest Suppl"},{"key":"7586_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"M Bradford","year":"1976","unstructured":"Bradford M (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principie of protein-dye binding. Anal Biochem 72:248\u2013254","journal-title":"Anal Biochem"},{"key":"7586_CR24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3109\/09537109609023582","volume":"7","author":"C Pilla","year":"1996","unstructured":"Pilla C, Emanuelli T, Frassetto SS et al (1996) ATP diphosphohydrolase activity (Apyrase, EC 3.6.1.5.) in human blood platelets. Platelets 7:225\u2013230","journal-title":"Platelets"},{"key":"7586_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0049-3848(03)00178-6","volume":"109","author":"GI Lunkes","year":"2003","unstructured":"Lunkes GI, Lunkes D, Stefanello F et al (2003) Enzymes that hydrolyze adenine nucleotides in diabetes and associated pathologies. Thromb Res 109:189\u2013194. https:\/\/doi.org\/10.1016\/S0049-3848(03)00178-6","journal-title":"Thromb Res"},{"key":"7586_CR26","unstructured":"Giusti G, Galanti B(1984) Adenosine deaminase: colorimetric method. HU Bergmeyer, Methods Enzym Anal 4:315\u2013323"},{"key":"7586_CR27","unstructured":"Metcalf JA, Gallin JI, Nauseef WM, Root RK(1986) Myeloperoxidase functional assays. In: Laboratory Manual of Neutrophil Function, Raven Press. pp\u00a0150\u2013151"},{"key":"7586_CR28","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.ccell.2019.10.007","volume":"36","author":"D Boison","year":"2019","unstructured":"Boison D, Yegutkin GG (2019) Adenosine Metabolism: Emerging Concepts for Cancer Therapy. Cancer Cell 36:582\u2013596. https:\/\/doi.org\/10.1016\/j.ccell.2019.10.007","journal-title":"Cancer Cell"},{"key":"7586_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.autneu.2015.04.011","volume":"191","author":"F Di Virgilio","year":"2015","unstructured":"Di Virgilio F, Vuerich M (2015) Purinergic signaling in the immune system. Auton Neurosci Basic Clin 191:117\u2013123. https:\/\/doi.org\/10.1016\/j.autneu.2015.04.011","journal-title":"Auton Neurosci Basic Clin"},{"key":"7586_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/cei.13157","volume":"194","author":"MN Theodoraki","year":"2018","unstructured":"Theodoraki MN, Hoffmann TK, Jackson EK, Whiteside TL (2018) Exosomes in HNSCC plasma as surrogate markers of tumour progression and immune competence. Clin Exp Immunol 194:67\u201378. https:\/\/doi.org\/10.1111\/cei.13157","journal-title":"Clin Exp Immunol"},{"key":"7586_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1158\/1078-0432.CCR-17-1261","volume":"24","author":"TL Whiteside","year":"2018","unstructured":"Whiteside TL (2018) Head and neck carcinoma immunotherapy: Facts and hopes. Clin Cancer Res 24:6\u201313. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1261","journal-title":"Clin Cancer Res"},{"key":"7586_CR32","first-page":"1","volume":"73","author":"D Allard","year":"2016","unstructured":"Allard D, Chrobak P, Stagg J (2016) CD73 \u2013 adenosine: a next-generation target in immuno-oncology. Immunotherapy 73:1\u201319","journal-title":"Immunotherapy"},{"key":"7586_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.00925","volume":"10","author":"S Vigano","year":"2019","unstructured":"Vigano S, Alatzoglou D, Irving M et al (2019) Targeting adenosine in cancer immunotherapy to enhance T-Cell function. Front Immunol 10:1\u201330. https:\/\/doi.org\/10.3389\/fimmu.2019.00925","journal-title":"Front Immunol"},{"key":"7586_CR34","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3390\/cancers12061602","volume":"12","author":"N Ludwig","year":"2020","unstructured":"Ludwig N, Gillespie DG, Reichert TE et al (2020) Purine Metabolites in Tumor-Derived Exosomes May Squamous Cell Carcinoma. Cancers (Basel) 12:1602. https:\/\/doi.org\/10.3390\/cancers12061602","journal-title":"Cancers (Basel)"},{"key":"7586_CR35","doi-asserted-by":"publisher","unstructured":"De Leve S, Wirsd\u00f6rfer F, Jendrossek V (2019) Targeting the immunomodulatory CD73\/adenosine system to improve the therapeutic gain of radiotherapy. Front Immunol 10. https:\/\/doi.org\/10.3389\/fimmu.2019.00698","DOI":"10.3389\/fimmu.2019.00698"},{"key":"7586_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.imlet.2018.05.001","volume":"205","author":"D Allard","year":"2019","unstructured":"Allard D, Chrobak P, Allard B et al (2019) Targeting the CD73-adenosine axis in immuno-oncology. Immunol Lett 205:31\u201339. https:\/\/doi.org\/10.1016\/j.imlet.2018.05.001","journal-title":"Immunol Lett"},{"key":"7586_CR37","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.2217\/imt-2019-0147","volume":"11","author":"F Jadidi-Niaragh","year":"2019","unstructured":"Jadidi-Niaragh F (2019) Potential of CD73 as a target for cancer immunotherapy. Immunotherapy 11:1353\u20131355. https:\/\/doi.org\/10.2217\/imt-2019-0147","journal-title":"Immunotherapy"},{"key":"7586_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0360-8","volume":"6","author":"RD Leone","year":"2018","unstructured":"Leone RD, Emens LA (2018) Targeting adenosine for cancer immunotherapy. J Immunother Cancer 6:1\u20139. https:\/\/doi.org\/10.1186\/s40425-018-0360-8","journal-title":"J Immunother Cancer"},{"key":"7586_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0165-2478(03)00087-7","volume":"88","author":"P Conti","year":"2003","unstructured":"Conti P, Kempuraj D, Frydas S et al (2003) IL-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26. Immunol Lett 88:171\u2013174. https:\/\/doi.org\/10.1016\/S0165-2478(03)00087-7","journal-title":"Immunol Lett"},{"key":"7586_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem_20190418","volume":"217","author":"M Saraiva","year":"2020","unstructured":"Saraiva M, Saraiva M, Vieira P et al (2020) Biology and therapeutic potential of interleukin-10. J Exp Med 217:1\u201319. https:\/\/doi.org\/10.1084\/jem_20190418","journal-title":"J Exp Med"},{"key":"7586_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0139598","volume":"10","author":"S Zhao","year":"2015","unstructured":"Zhao S, Wu D, Wu P et al (2015) Serum IL-10 predicts worse outcome in cancer patients: A meta-analysis. PLoS ONE 10:1\u201315. https:\/\/doi.org\/10.1371\/journal.pone.0139598","journal-title":"PLoS ONE"},{"key":"7586_CR42","doi-asserted-by":"publisher","first-page":"155082","DOI":"10.1016\/j.cyto.2020.155082","volume":"130","author":"DB Torres-Pineda","year":"2020","unstructured":"Torres-Pineda DB, Mora-Garc\u00eda M, de L, Garc\u00eda-Rocha R et al (2020) Adenosine augments the production of IL-10 in cervical cancer cells through interaction with the A2B adenosine receptor, resulting in protection against the activity of cytotoxic T cells. Cytokine 130:155082. https:\/\/doi.org\/10.1016\/j.cyto.2020.155082","journal-title":"Cytokine"},{"key":"7586_CR43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cca.2019.02.022","volume":"493","author":"G Ndrepepa","year":"2019","unstructured":"Ndrepepa G (2019) Myeloperoxidase \u2013 A bridge linking inflammation and oxidative stress with cardiovascular disease. Clin Chim Acta 493:36\u201351. https:\/\/doi.org\/10.1016\/j.cca.2019.02.022","journal-title":"Clin Chim Acta"},{"key":"7586_CR44","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.imbio.2010.01.002","volume":"215","author":"M Jaganjac","year":"2010","unstructured":"Jaganjac M, Poljak-Blazi M, Kirac I et al (2010) Granulocytes as effective anticancer agent in experimental solid tumor models. Immunobiology 215:1015\u20131020. https:\/\/doi.org\/10.1016\/j.imbio.2010.01.002","journal-title":"Immunobiology"},{"key":"7586_CR45","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrc.2017.86","volume":"17","author":"D Vijayan","year":"2017","unstructured":"Vijayan D, Young A, Teng MWL, Smyth MJ (2017) Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer 17:709\u2013724. https:\/\/doi.org\/10.1038\/nrc.2017.86","journal-title":"Nat Rev Cancer"},{"key":"7586_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms19123837","volume":"19","author":"K Sek","year":"2018","unstructured":"Sek K, M\u00f8lck C, Stewart GD et al (2018) Targeting adenosine receptor signaling in cancer immunotherapy. Int J Mol Sci 19:1\u201323. https:\/\/doi.org\/10.3390\/ijms19123837","journal-title":"Int J Mol Sci"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07586-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-022-07586-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07586-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T03:47:39Z","timestamp":1744170459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-022-07586-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["7586"],"URL":"https:\/\/doi.org\/10.1007\/s11033-022-07586-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"14 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Human Ethics Committee of the Federal University of Fronteira Sul (Chapec\u00f3, SC, Brazil), with the number CAAE 03057018.6.0000.5564 and approval protocol number 3.105.374.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}}]}}